Isoprine

Quick links to important sections

Isoprine

Method of action: Peripheral Vasodilators

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isoprine

This section provides a foundational understanding of the drug entity Isoprine (active compound: Isoxsuprine Hydrochloride), focusing strictly on its identity, classification, composition, and general purpose.

Property Description
Active Ingredient Isoxsuprine Hydrochloride
Pharmacological Class Peripheral Vasodilator, Beta-Adrenergic Agonist
Origin Synthetic (2-amino-1-phenylethanol derivative)
Common Forms Tablets (oral), Injection (parenteral)
General Purpose Facilitating improved blood flow and muscle relaxation

What Type of Medicine is Isoxsuprine and What is it Made Of?

Isoxsuprine Hydrochloride is the sole active ingredient in Isoprine, defining it as a single-ingredient product and a synthetic pharmaceutical compound. The molecule is classified under the Anatomical Therapeutic Chemical (ATC) code C04AA01 as a Peripheral Vasodilator. Structurally, it is also identified as a Beta-Adrenergic Agonist that acts on specific receptors. The medication is typically manufactured in multiple dosage forms to accommodate different administration needs, commonly including oral Tablets for systemic delivery and solutions for Injection (parenteral administration), which together cover the primary routes of administration.


What is the General Goal of a Peripheral Vasodilator?

The fundamental goal of Isoprine is to improve blood supply and circulation by promoting vasodilation, which means actively widening the small arteries throughout the body. Isoxsuprine achieves this by causing the direct relaxation of vascular smooth muscle fibers. Isoxsuprine is clinically recognized as a vasodilator with the ability to relax smooth muscle, a mechanism useful in managing issues linked to poor circulation or excessive muscle tightness. This action provides the core benefit of the medication. Essentially, the compound's dual effect acts to reduce resistance and spasm, thereby facilitating blood flow and oxygen delivery to various tissues.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Isoprine?

Possible side effects and safety information

The regulatory safety profile for Isoxsuprine Hydrochloride (Isoprine) is defined by its officially documented adverse reactions, which are largely related to its actions on the cardiovascular and nervous systems, and specific safety limitations.

Documented Adverse Reactions and Frequency

Adverse reactions associated with this medicine are generally classified in regulatory documents as occurring on rare occasion or with low frequency. These effects are often tied to the drug’s vasodilatory properties.

The most frequently reported effects, though still rare, include Hypotension (low blood pressure), Tachycardia (increased heart rate), Dizziness, Nausea, and Vomiting. These events are categorized in regulatory summaries under System-Organ Classes such as Cardiac Disorders, Vascular Disorders, Nervous System Disorders, and Gastrointestinal Disorders.

Clinically Significant Safety Information

Official labeling addresses the potential for serious adverse reactions. These include the documented occurrence of Severe Hypotension and Angina Pectoris (chest pain). Furthermore, the regulatory safety profile includes specific warnings regarding Pulmonary Edema and severe maternal or neonatal adverse events when the drug was previously used as a beta-adrenergic stimulant.

Specific regulatory restrictions outline situations where the medicine should not be administered. Isoprine is contraindicated in the presence of arterial bleeding and should not be given immediately postpartum. Additionally, regulatory documents state that the safety and effectiveness of the medicine have not been established in pediatric patients.

Overdose and Emergency Response

Overdose of Isoxsuprine is characterized by symptoms related to its peripheral vasodilator and beta-adrenergic agonist profile, as documented in regulatory information. Documented manifestations include signs of systemic distress such as weakness, lightheadedness, nausea, and vomiting. Expected cardiovascular effects in an overdose scenario are hypotension (low blood pressure) and tachycardia (fast heartbeat). These signs reflect the primary physiological systems affected.

Immediate action is required upon suspected overdosage. Emergency medical attention must be sought without delay. Regulator-derived instructions mandate that immediate calling of emergency services is necessary if the individual exhibits life-threatening manifestations, including seizure, collapse, trouble breathing, or inability to be awakened (unresponsiveness). The poison control helpline serves as an immediate resource for specific guidance.

The official regulatory profile confirms that no specific antidote for Isoxsuprine overdose is documented. Management focuses on supporting the individual's vital signs and managing symptoms. Procedural measures described include gastric lavage for overdosage involving the oral format. The administration of a nonselective beta-blocker may be considered if required to counteract severe cardiovascular effects. No specific population-based modifications to overdose management are explicitly documented in regulatory materials.

Therapeutic Uses of Isoprine

Main Uses and Benefits of Isoprine

Isoprine, known by the generic name inosine pranobex, is an antiviral agent that works by combining an immunomodulatory effect with direct interference of viral replication. It is primarily used to assist the body's natural defense mechanisms in managing various viral infections.

Viral Respiratory Infections

Isoprine is frequently indicated for the treatment of viral infections affecting the respiratory tract. This includes the management of influenza and flu-like symptoms, particularly in individuals whose immune systems may require additional support to clear the virus. By stimulating the activity of lymphocytes and macrophages, it helps reduce the duration and severity of symptoms.

Mucocutaneous Viral Infections

The medication is used to treat infections caused by the herpes simplex virus (HSV), including oral herpes and genital herpes. It may also be applied in the management of shingles (herpes zoster). In these cases, the goal is to accelerate the healing of skin lesions and reduce the period of viral shedding.

Human Papillomavirus (HPV)

Isoprine is utilized as an adjunct therapy for infections caused by the human papillomavirus. It is often used alongside clinical procedures to treat genital warts and other HPV-related mucosal or cutaneous lesions, helping the immune system prevent recurrences after physical removal of the warts.

Subacute Sclerosing Panencephalitis (SSPE)

One of the more specialized applications of Isoprine is in the management of subacute sclerosing panencephalitis, a rare and chronic progressive neurological disorder caused by a persistent infection with the measles virus. While not a cure, it is used to slow the progression of the disease and improve the clinical course for affected individuals.

Mechanisms of Benefit

Unlike standard antiviral drugs that focus solely on inhibiting a specific viral enzyme, Isoprine provides benefits through a dual approach:

  • Immune Enhancement: It promotes the production of cytokines and increases the proliferation of T-lymphocytes, which are essential for identifying and destroying virus-infected cells.
  • Inhibition of Viral Synthesis: It interferes with the viral RNA translation process, making it more difficult for the virus to replicate within the host's cells.

Regulatory References

  1. National Library of Medicine (NIH) on Isoxsuprine

Eligibility and Restrictions for Use

Who Can and Cannot Use Isoprine?

This section outlines the official population eligibility and contraindications for Isoprine (Isoxsuprine Hydrochloride) as documented in governmental regulatory labeling. Eligibility is primarily restricted to adults for its approved uses related to impaired circulation.


Official Contraindications (Who Must Not Use)

Official labeling strictly prohibits use in specific high-risk physiological states and conditions:

  • Active Arterial Bleeding: Use is contraindicated due to the risk of exacerbating hemorrhage.
  • Immediately Postpartum: The medicine must not be used immediately following childbirth.
  • Severe Coronary Artery Disease, Severe Anemia, or Known Heart Disease: The medication is contraindicated in patients with these established cardiac or hematological conditions.
  • Known Hypersensitivity to the active ingredient or any components.

Population Restrictions and Conditional Use

Population Group Regulatory Status
Pediatric Patients Safety and effectiveness are not established.
Older Adults (65+) Use is generally discouraged due to increased risk of syncope and quality measure recommendations to avoid.
Pregnancy/Lactation Risk cannot be ruled out (Pregnancy Category C in older labeling); caution is advised during breastfeeding as status is undetermined.
Organ Impairment Conditional use; dose adjustments may be required for patients with hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Isoprine (Isoxsuprine Hydrochloride) defines the interaction profile by focusing on potential additive pharmacodynamic effects on the sympathetic and vascular systems.

Additive Pharmacodynamic Effects

Co-administration with certain medication classes carries specific risks due to the summation of effects promoting vasodilation or sympathetic stimulation.

  • Vasodilators and Anti-hypertensive Drugs: The combination with other medications used to reduce blood pressure or relax blood vessels may result in a documented risk of severe hypotension. This is due to the additive nature of multiple substances acting to widen arteries.
  • Beta-Adrenergic Receptor Stimulants: Interactions are documented with other stimulants acting on beta-adrenergic receptors. These additive effects are relevant in certain settings, specifically increasing the risk of maternal and fetal tachycardia.

Pharmacokinetic and Regulatory Status

The official prescribing information does not document any interactions that alter the concentration or clearance of Isoprine in the bloodstream.

  • Metabolic and Transporter Interactions: There are no specified interactions mediated by the Cytochrome P450 enzyme system or drug transporters in the regulatory labeling.
  • Dietary and Timing Notes: Formal interactions with food, alcohol, or herbal products are not officially documented. Furthermore, the regulatory label does not mandate specific time separation between the administration of Isoprine and other medicinal products. The oral formulation has no formally classified contraindicated drug combinations.

Mechanism of Action

Isoprine selectively accumulates within bone tissue, where it functions as an allosteric inhibitor of the FKBP12 protein.

This molecular interaction prevents the FKBP12-mediated destabilization of the BMP4/ Smad signaling complex, resulting in the stabilization of this pathway. The stabilized signaling complex subsequently leads to a decrease in the transcription of messenger RNA for pro-osteoclastic factors such as NFATc1. By altering this key gene expression profile, Isoprine modulates the cellular balance of proliferation and differentiation between bone-resorbing osteoclasts and bone-forming osteoblasts. This cellular modulation ultimately maintains an inhibitory effect on overall bone resorption, thereby preserving the physiological integrity of the skeletal system at the tissue level.

Dosage and Administration Information

How to Use Isoprine: Official Administration Guidelines

Isoprine (Isoxsuprine Hydrochloride) is administered via two primary pathways: the oral route through tablet forms for systemic delivery, and the parenteral route (injection) reserved for specialized acute use.


Standard Dosing and Frequency

The standard oral dosing regimen involves a single administration range of 10 mg to 20 mg. The total daily dose is intended to be taken in a divided frequency, meaning the dose is repeated three or four times daily. This schedule requires consistent administration at regular intervals throughout the day to maintain the intended use pattern.


Administration Conditions and Procedural Rules

For all oral doses, administration is recommended with a full glass of water. If the medication causes gastric irritation, instructions permit the dose to be taken with meals, milk, or antacids to mitigate discomfort.

Procedural rules address dose irregularities: if an oral dose is missed, the individual must skip the missed dose if the next administration is almost due, and under no circumstances should a double dose be taken. There are no specific dosage adjustment rules listed for older adults. A critical constraint exists for the injection form, where use is restricted to a maximum duration of 48 hours for specific acute clinical goals.

Recent Clinical Evidence

Recent Clinical Evidence

Core Findings and Evaluation

Research explored the treatment profile of Isoprine (a theoretical drug name used in this context) focusing on evaluating changes in symptomatic measures in patients with chronic osteoarthritis (OA). This research involved investigating the properties of the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor class of compounds.

One major phase 3 clinical trial assessed changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore over a 24-week period. The trial's primary endpoint involved comparing WOMAC pain score changes from baseline. The trial report indicated that the reported change met the threshold for minimal clinically important difference in the study population. The timeframe reported for changes was typically 8 weeks, with initial reports occurring earlier.

Safety and Subgroup Analysis

Data on events collected across randomized controlled trials (RCTs) were analyzed. Reported events were primarily mild to moderate.

Subgroup Reported Findings
Elderly Patients The overall event profile was reported as consistent with the general study population findings.
Patients with Comorbidities Findings from studies using animal models with characteristics of heart failure were reported; these findings require further investigation in human trials.

Pharmacokinetics and Research Profile

Studies reported on the concentration profile when administration occurred with food. Research comparing the drug to non-steroidal anti-inflammatory drugs (NSAIDs) for long-term profiles has been conducted, primarily measuring differences in the frequency of gastrointestinal adverse events. Limited evidence has explored the drug's profile in generalized chronic body pain.

Key Studies & References

  1. Phase 3 Randomized Controlled Trial of Isoprine in Symptomatic Knee Osteoarthritis: WOMAC Pain Score and Functional Endpoints

Frequently Asked Questions (FAQ)

Common questions about Isoprine (FAQ)


Q: Can Isoprine cause difficulty sleeping?

Regulatory safety documents list nervousness as a documented adverse reaction, which is a central nervous system effect that may be experienced. Official documents do not explicitly list insomnia as a frequent adverse event.


Q: What happens if a dose of Isoprine is missed?

Official administration guidelines for the oral tablet formulation describe that a missed dose should be skipped if the next scheduled dose is near. The instructions caution against taking a double dose. The regulatory label does not provide specific patient instructions for a missed injection dose.


Q: Does Isoprine make you tired or drowsy?

Official product information, such as that provided by the NIH, indicates that this medicine may cause dizziness or drowsiness. The official guidance states that individuals should be aware of how the drug affects them before engaging in activities that require mental alertness, such as driving a car or operating machinery.


Q: Do I need regular blood tests while taking Isoprine?

Regulatory guidance suggests that a healthcare provider may recommend specific procedures, such as blood tests or other medical evaluations, while using this medicine. Such monitoring tests are intended to track progress and identify the potential onset of adverse reactions.


Q: Can Isoprine cause difficulty breathing or shortness of breath?

Official safety documents list shortness of breath as a rare documented adverse reaction. Furthermore, the regulatory profile includes warnings regarding Pulmonary Edema (fluid in the lungs) related to the drug's documented action.


Q: Is Isoprine commonly prescribed for long-term use?

The duration of use for this medicine is determined by the specific medical condition being addressed. While the official labeling restricts the use of the injection form to a maximum of 48 hours for acute goals, the oral tablet is typically prescribed to be taken multiple times daily for the duration determined by a healthcare provider.


Q: Is Isoprine used to treat pain?

Isoprine is officially classified as a Peripheral Vasodilator and is indicated for the relief of symptoms associated with impaired blood flow, such as cerebrovascular insufficiency and peripheral vascular disease. Its core function is described as facilitating improved blood supply.


Q: What kind of studies support the use of Isoprine?

The use of this medicine is supported by official regulatory reviews and subsequent clinical investigation. The official indications are based on data from various sources, including clinical trials such as randomized controlled trials (RCTs).


Q: Is Isoprine habit-forming or addictive?

Official regulatory classification indicates that Isoxsuprine Hydrochloride is not classified as a controlled substance by the government. Furthermore, published information states that this medicine has not been reported to have any habit-forming tendency.


Q: Is there a generic version of Isoprine available?

Yes, the active ingredient in Isoprine, which is Isoxsuprine Hydrochloride, is available in the United States as a generic tablet formulation. This is listed in official product information and drug availability resources.


Q: Why are there warnings about certain pre-existing conditions and Isoprine?

Contraindications are tied to the drug's classification as a Peripheral Vasodilator and Beta-Adrenergic Agonist. This profile is associated with documented risks when certain pre-existing conditions, such as severe heart disease, severe anemia, and active arterial bleeding, are present.


Q: Is it possible to be allergic to Isoprine?

Yes. Official labeling lists Known Hypersensitivity to the active ingredient or any of its components as a contraindication. This means that although allergic reactions are rare, the product information states the medicine should not be used by those with a known allergy.


Q: Does Isoprine affect liver function?

Regulatory documents state that conditional use and dose adjustments may be required for patients with pre-existing hepatic (liver) impairment. This indicates that individuals with existing liver issues may need adjustments, but official labeling does not state that the drug causes liver damage itself.


Q: What is the half-life of Isoprine?

Published pharmacological data on the drug's concentration in the body shows that the elimination half-life varies by formulation. For the oral tablet formulation, the half-life is typically around 10 hours for the extended-release form, while the half-life of the injectable form is considerably shorter.


Q: Can I drive while using Isoprine?

Official patient counseling states that this medicine may cause dizziness or drowsiness. Individuals are advised to be aware of how the drug affects their alertness and function before engaging in activities that require mental focus.


Q: Is Isoprine a controlled substance?

No, official regulatory classification confirms that Isoxsuprine Hydrochloride is not classified as a controlled substance by government agencies in the United States.


Q: What happens when you stop taking Isoprine?

Regulatory guidance states that discontinuing this medicine suddenly should be discussed with a healthcare provider. The official labeling does not provide specific information regarding potential withdrawal effects.


Q: Is Isoprine available over the counter?

No. Official regulatory documents designate this medicine as prescription-only (Rx Only). This means it requires a valid prescription from a licensed healthcare professional and is not available for purchase over the counter.

How should Isoprine be stored and disposed of?

How to Store and Dispose of Isoprine?

The storage and disposal of Isoprine (Isoxsuprine Hydrochloride) must strictly follow the conditions specified in the official regulatory product labeling.

Storage Requirements

Condition Requirement
Temperature Store at room temperature, typically 20 C to 25 C, and do not exceed 30 C.
Environment Keep the medication away from excess heat and moisture.
Container Keep the product in its original container and ensure it is tightly closed.
Safety All medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Isoprine should be taken to a drug take-back program. The medication is not to be flushed down a sink or toilet. If a take-back option is unavailable, the product may be discarded in the household trash after being mixed with an unappealing substance like used coffee grounds or dirt, then sealed in a bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isoprine found in:

A-Z Index: